[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053964":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":30,"centralContacts":41,"locations":47,"responsibleParty":201,"collaborators":30,"id":203,"slug":204,"hasResults":205,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":205,"sex":211,"minAge":212,"maxAge":30,"enrollmentInfo":213,"targetDuration":30,"studyType":216,"phases":217,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":78,"whyStopped":30,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":242},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: SC Durvalumab DL1","EXPERIMENTAL","Participants will receive DL1 of SC durvalumab + rHu followed by IV durvalumab at predefined intervals.",[13,14,15],"Drug: SC durvalumab + rHu","Drug: IV durvalumab","Drug: Tremelimumab",{"label":17,"type":10,"description":18,"interventionNames":19},"Part 1: SC Durvalumab DL2","Participants will receive DL2 of SC durvalumab + rHu followed by IV durvalumab at predefined intervals.",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"Part 2: Expansion Cohort, SC Durvalumab Dose Level X","Participants will receive dose level X (determined from data analysis in Part 1) of SC durvalumab + rHu followed by IV durvalumab at predefined intervals.",[13,14,15],[25,31,37],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","SC durvalumab + rHu","Durvalumab + rHu will be administered subcutaneously.",[9,17,21],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"IV durvalumab","Durvalumab will be administered intravenously.",[9,17,21],[36],"MEDI4736",{"type":26,"name":38,"description":39,"armGroupLabels":40,"otherNames":30},"Tremelimumab","Tremelimumab will be administered to participants with unresectable HCC as an IV infusion.",[9,17,21],[42],{"name":43,"role":44,"phone":45,"phoneExt":30,"email":46},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[48,61,69,77,88,96,101,111,119,127,135,143,152,160,165,170,180,188,193],{"facility":49,"status":50,"city":51,"state":30,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":30},"Research Site","NOT_YET_RECRUITING","Fitzroy","3065","Australia","AU",{"type":56,"coordinates":57},"Point",[58,59],144.97833,-37.79839,{"lat":59,"lon":58},{"facility":49,"status":50,"city":62,"state":30,"zip":63,"country":53,"countryCode":54,"cosmosGeoPoint":64,"geoPoint":68,"contacts":30},"St Albans","3021",{"type":56,"coordinates":65},[66,67],144.80049,-37.74496,{"lat":67,"lon":66},{"facility":49,"status":50,"city":70,"state":30,"zip":71,"country":53,"countryCode":54,"cosmosGeoPoint":72,"geoPoint":76,"contacts":30},"Woolloongabba","4102",{"type":56,"coordinates":73},[74,75],153.03655,-27.48855,{"lat":75,"lon":74},{"facility":49,"status":78,"city":79,"state":30,"zip":80,"country":81,"countryCode":82,"cosmosGeoPoint":83,"geoPoint":87,"contacts":30},"RECRUITING","Batumi","6010","Georgia","GE",{"type":56,"coordinates":84},[85,86],41.6306,41.64077,{"lat":86,"lon":85},{"facility":49,"status":78,"city":89,"state":30,"zip":90,"country":81,"countryCode":82,"cosmosGeoPoint":91,"geoPoint":95,"contacts":30},"Tbilisi","0112",{"type":56,"coordinates":92},[93,94],44.83412,41.69143,{"lat":94,"lon":93},{"facility":49,"status":78,"city":89,"state":30,"zip":97,"country":81,"countryCode":82,"cosmosGeoPoint":98,"geoPoint":100,"contacts":30},"0114",{"type":56,"coordinates":99},[93,94],{"lat":94,"lon":93},{"facility":49,"status":78,"city":102,"state":30,"zip":103,"country":104,"countryCode":105,"cosmosGeoPoint":106,"geoPoint":110,"contacts":30},"Brzozów","36-200","Poland","PL",{"type":56,"coordinates":107},[108,109],22.01926,49.69501,{"lat":109,"lon":108},{"facility":49,"status":50,"city":112,"state":30,"zip":113,"country":104,"countryCode":105,"cosmosGeoPoint":114,"geoPoint":118,"contacts":30},"Koszalin","75-581",{"type":56,"coordinates":115},[116,117],16.17222,54.19438,{"lat":117,"lon":116},{"facility":49,"status":78,"city":120,"state":30,"zip":121,"country":104,"countryCode":105,"cosmosGeoPoint":122,"geoPoint":126,"contacts":30},"Lublin","20-090",{"type":56,"coordinates":123},[124,125],22.57009,51.25058,{"lat":125,"lon":124},{"facility":49,"status":78,"city":128,"state":30,"zip":129,"country":104,"countryCode":105,"cosmosGeoPoint":130,"geoPoint":134,"contacts":30},"Olsztyn","10-357",{"type":56,"coordinates":131},[132,133],20.49272,53.78376,{"lat":133,"lon":132},{"facility":49,"status":78,"city":136,"state":30,"zip":137,"country":104,"countryCode":105,"cosmosGeoPoint":138,"geoPoint":142,"contacts":30},"Przemyśl","37-700",{"type":56,"coordinates":139},[140,141],22.76728,49.78498,{"lat":141,"lon":140},{"facility":49,"status":78,"city":144,"state":30,"zip":145,"country":146,"countryCode":30,"cosmosGeoPoint":147,"geoPoint":151,"contacts":30},"Seongnam-si","13620","South Korea",{"type":56,"coordinates":148},[149,150],127.13778,37.43861,{"lat":150,"lon":149},{"facility":49,"status":78,"city":153,"state":30,"zip":154,"country":146,"countryCode":30,"cosmosGeoPoint":155,"geoPoint":159,"contacts":30},"Seoul","03722",{"type":56,"coordinates":156},[157,158],126.9784,37.566,{"lat":158,"lon":157},{"facility":49,"status":78,"city":153,"state":30,"zip":161,"country":146,"countryCode":30,"cosmosGeoPoint":162,"geoPoint":164,"contacts":30},"06351",{"type":56,"coordinates":163},[157,158],{"lat":158,"lon":157},{"facility":49,"status":78,"city":153,"state":30,"zip":166,"country":146,"countryCode":30,"cosmosGeoPoint":167,"geoPoint":169,"contacts":30},"5505",{"type":56,"coordinates":168},[157,158],{"lat":158,"lon":157},{"facility":49,"status":78,"city":171,"state":30,"zip":172,"country":173,"countryCode":174,"cosmosGeoPoint":175,"geoPoint":179,"contacts":30},"Tainan","73657","Taiwan","TW",{"type":56,"coordinates":176},[177,178],120.21333,22.99083,{"lat":178,"lon":177},{"facility":49,"status":78,"city":181,"state":30,"zip":182,"country":173,"countryCode":174,"cosmosGeoPoint":183,"geoPoint":187,"contacts":30},"Taipei","110",{"type":56,"coordinates":184},[185,186],121.52639,25.05306,{"lat":186,"lon":185},{"facility":49,"status":50,"city":181,"state":30,"zip":189,"country":173,"countryCode":174,"cosmosGeoPoint":190,"geoPoint":192,"contacts":30},"112",{"type":56,"coordinates":191},[185,186],{"lat":186,"lon":185},{"facility":49,"status":50,"city":194,"state":30,"zip":195,"country":173,"countryCode":174,"cosmosGeoPoint":196,"geoPoint":200,"contacts":30},"Taoyuan","333",{"type":56,"coordinates":197},[198,199],121.29696,24.99368,{"lat":199,"lon":198},{"type":202,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100053964","phase-1-a-phase-i-dose-escalation-and-dose-expansion-study-to-investigate-the-pharmacokinetics-and-safety-of-subcutaneous-durvalumab-100053964",false,"NCT07391670","A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab","A Phase I, Multicentre, Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab in Adult Participants With Solid Tumours","IMFINZI-subQ","Inclusion Criteria:\n\n* An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy of ≥ 12 weeks at enrolment.\n* Adequate organ and marrow function.\n* Minimum body weight \\> 30 kg.\n\nPart 1 only:\n\nLocally Advanced Unresectable (Stage III) NSCLC Participants -\n\n* Histological or cytological documented evidence of NSCLC (locally advanced, unresectable, Stage III).\n* Must have received at least 2 cycles of platinum-based chemotherapy concurrent with definitive radiation therapy.\n* Have not progressed following definitive concurrent chemoradiation.\n\nLS-SCLC Participants -\n\n* Histologically or cytologically documented LS-SCLC (Stage I-III).\n* Received 4 cycles of chemotherapy concurrent with radiotherapy, which must be completed within 1 to 42 days prior to enrolment.\n* Have not progressed following definitive concurrent chemoradiation.\n\nPart 1 and 2:\n\nUnresectable HCC Participants -\n\n* Unresectable HCC based on histopathological confirmation.\n* No prior systemic therapy for unresectable HCC.\n* Must not be eligible for locoregional therapy for unresectable HCC.\n* Child-Pugh Score class A.\n* Measurable disease as defined by RECIST v1.1.\n\nExclusion Criteria:\n\n* Active or prior documented autoimmune disease requiring systemic treatment.\n* Uncontrolled infection (including human immunodeficiency virus \\[HIV\\], hepatitis B or C).\n* Prior exposure to immune checkpoint inhibitors.\n\nPart 1 only:\n\nLocally Advanced Unresectable (Stage III) NSCLC Participants -\n\n* Mixed SCLC and NSCLC histology.\n* Active pneumonitis or interstitial lung disease requiring systemic therapy.\n\nLS SCLC Participants -\n\n* Mixed SCLC and NSCLC histology.\n* Extensive-stage disease.\n* History of Grade ≥ 2 pneumonitis.\n\nPart 1 and 2:\n\nUnresectable HCC Participants -\n\n* Hepatic encephalopathy.\n* Uncontrolled ascites.\n* Active gastrointestinal (GI) bleeding.","ALL","18 Years",{"count":214,"type":215},40,"ESTIMATED","INTERVENTIONAL",[218],"PHASE1","The purpose of the study is to determine a subcutaneous (SC: under the skin) durvalumab + recombinant human hyaluronidase (rHu) dose that yields systemic drug exposure similar to intravenous (IV: into the veins) durvalumab administration and to evaluate the pharmacokinetics and safety of SC durvalumab + rHu injection in participants with different types of solid tumours (cancers).",[221],"Solid Tumours",[223,224,225,226,227,228,229,230,231,232],"Pharmacokinetics","Non-small cell lung cancer (Stage III, unresectable)","Small cell lung cancer (Limited stage)","Hepatocellular carcinoma (Unresectable)","Subcutaneous","Human hyaluronidase","Monoclonal antibody","Programmed cell death ligand 1 (PD-L1)","Programmed cell death protein 1","Anticancer therapy","2026-07-10",{"date":235,"type":236},"2026-07-13","ACTUAL",{"date":238,"type":236},"2026-03-31",{"date":240,"type":215},"2027-08-30",{"name":5,"class":6},19]